NEUROBO PHARMACEUTICALS, INC. Financials NeuroBo Pharmaceuticals, Inc.
Equities
NRBO
US64132R4048
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.54 USD | +0.22% |
|
-2.99% | +22.82% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 136.8 | 86.24 | 32.44 | 13.61 | 17.93 | 37.21 | - | - |
| Enterprise Value (EV) 1 | 136.8 | 86.24 | 32.44 | 13.61 | 17.93 | 37.21 | 37.21 | 37.21 |
| P/E ratio | -2.14 x | -2.87 x | -1.85 x | -0.13 x | -1.5 x | -1.09 x | -1.86 x | -2.18 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | -1.16 x | - | -1.55 x | -1.66 x | -1.77 x |
| FCF Yield | - | - | - | -86% | - | -64.5% | -60.3% | -56.4% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 65.1 | 68.4 | 111 | 2,372 | 4,852 | 8,214 | - | - |
| Reference price 2 | 2,100 | 1,260 | 292.8 | 5.740 | 3.697 | 4.540 | 4.540 | 4.540 |
| Announcement Date | 3/30/20 | 4/15/21 | 3/31/22 | 3/30/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -20.18 | -29.72 | - | -19.63 | -15.89 | -28.92 | -30.19 | -34.61 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -21.31 | -29.68 | - | -13.97 | -12.47 | -28.7 | -30.03 | -34.44 |
| Net income 1 | -21.31 | -29.68 | -15.28 | -13.97 | -12.47 | -28.7 | -30.03 | -34.44 |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -979.2 | -439.2 | -158.4 | -43.44 | -2.460 | -4.163 | -2.440 | -2.083 |
| Free Cash Flow 1 | - | - | - | -11.71 | - | -24 | -22.44 | -20.99 |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 4/15/21 | 3/31/22 | 3/30/23 | 3/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | -10.43 | -2.52 | -3.806 | -3.893 | -5.667 | -6.881 | -6.787 | -7.303 | -7.938 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | - | -4.676 | -2.604 | -0.734 | -3.818 | -5.314 | -6.714 | -6.754 | -7.29 | -7.889 |
| Net income 1 | -3.113 | -4.676 | -2.604 | -0.734 | -3.818 | -5.314 | -6.714 | -6.754 | -7.29 | -7.889 |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -28.00 | - | -0.4800 | -0.1600 | -0.7200 | -2.280 | -1.320 | -1.127 | -0.9367 | -0.8833 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/14/22 | 3/30/23 | 5/12/23 | 8/9/23 | 11/13/23 | 3/28/24 | 5/9/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | -11.7 | - | -24 | -22.4 | -21 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 3/30/20 | 4/15/21 | 3/31/22 | 3/30/23 | 3/28/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
4.53
USD
Average target price
27.67
USD
Spread / Average Target
+510.74%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +22.82% | 37.21M | |
| +20.82% | 125B | |
| +21.96% | 114B | |
| +25.30% | 26.73B | |
| -22.97% | 19.43B | |
| -18.10% | 16.22B | |
| -19.03% | 15.33B | |
| +11.66% | 14.42B | |
| -48.41% | 14.33B | |
| +54.78% | 14.2B |
- Stock Market
- Equities
- NRBO Stock
- Financials NeuroBo Pharmaceuticals, Inc.
